,Rank,NCTId,BriefTitle,SecondaryId,LeadSponsorName,LocationCountry
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,United States
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,Bulgaria
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,Canada
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,Czechia
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,Spain
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,2020-004785-19|U1111-1260-3962,Sanofi,Ukraine
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,2020-004505-32,Novartis Pharmaceuticals,France
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,2020-004505-32,Novartis Pharmaceuticals,Germany
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,2020-004505-32,Novartis Pharmaceuticals,Spain
74,75,NCT04756700,Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis,2020-A01801-38,Biogen,France
80,81,NCT04742400,"Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",21-N-0010,National Institute of Neurological Disorders and Stroke (NINDS),United States
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,United States
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Argentina
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Belgium
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Brazil
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Bulgaria
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Canada
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Czechia
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Denmark
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,France
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Germany
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Greece
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Hungary
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Italy
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Mexico
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Peru
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Poland
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Portugal
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Puerto Rico
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Russian Federation
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Spain
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Switzerland
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Turkey
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,Ukraine
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-000894-26,Hoffmann-La Roche,United Kingdom
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,United States
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Argentina
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Australia
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Belgium
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Brazil
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Canada
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Czechia
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Denmark
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,France
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Germany
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Greece
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Hungary
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Israel
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Italy
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Mexico
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Netherlands
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Peru
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Poland
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Portugal
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Russian Federation
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Spain
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Switzerland
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Turkey
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,Ukraine
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",2020-000893-69,Hoffmann-La Roche,United Kingdom
146,147,NCT04410965,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,U1111-1233-0136,Sanofi,China
192,193,NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,2019-001069-33|U1111-1223-4541,Sanofi,United Kingdom
197,198,NCT04147052,iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis,K23HD086154,Johns Hopkins University,United States
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,2016-002667-34,Hoffmann-La Roche,United States
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,2016-002667-34,Hoffmann-La Roche,Italy
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,2016-002667-34,Hoffmann-La Roche,Poland
229,230,NCT04054050,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,R03HD101056,Johns Hopkins University,United States
239,240,NCT04025554,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,19-N-0124,National Institute of Neurological Disorders and Stroke (NINDS),United States
258,259,NCT03934489,Emotion Regulation Skills Training for Individuals With MS and Their Support Partners,PP-1804-30860,Johns Hopkins University,United States
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Argentina
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Belgium
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Brazil
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Bulgaria
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Canada
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Croatia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Czechia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Denmark
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Estonia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Finland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,France
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Ireland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Italy
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Kuwait
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Mexico
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Netherlands
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Norway
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Poland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Portugal
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Slovakia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Slovenia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Spain
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Sweden
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,Turkey
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2017-004886-29,Hoffmann-La Roche,United Kingdom
360,361,NCT03589105,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",2018-000780-91,Hoffmann-La Roche,France
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Austria
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Belgium
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Czechia
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Denmark
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Finland
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",France
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Greece
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Hungary
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Italy
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Lithuania
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Netherlands
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Norway
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Poland
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Portugal
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Slovakia
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Spain
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",Sweden
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),2017-002632-17,"Merck KGaA, Darmstadt, Germany",United Kingdom
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Australia
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Austria
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Canada
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Czechia
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Finland
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",France
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Germany
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Hungary
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Israel
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Italy
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Poland
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Spain
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",Sweden
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2017-002631-42,"Merck KGaA, Darmstadt, Germany",United Kingdom
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Austria
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Belgium
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Canada
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Czechia
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Denmark
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Finland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,France
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Germany
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Hungary
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Israel
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Italy
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Norway
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Poland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Portugal
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Spain
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Sweden
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,Switzerland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,2017-001176-31,Bayer,United Kingdom
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,United States
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Australia
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Belgium
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Canada
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Czechia
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,France
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Germany
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Hungary
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Israel
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Italy
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Netherlands
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Poland
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Spain
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,Switzerland
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),2017-001224-22,Biogen,United Kingdom
443,444,NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,U1111-1183-8711,Sanofi,United States
443,444,NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,U1111-1183-8711,Sanofi,Canada
463,464,NCT03134573,Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study,BF1504,Bayer,Germany
536,537,NCT02784210,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,16-N-0114,National Institute of Neurological Disorders and Stroke (NINDS),United States
549,550,NCT02740361,Online Program to Reduce Depression in MS,RG-1507-05418,"Charite University, Berlin, Germany",United States
549,550,NCT02740361,Online Program to Reduce Depression in MS,RG-1507-05418,"Charite University, Berlin, Germany",Germany
568,569,NCT02659956,Pathological Basis of MRI Signal Changes in Multiple Sclerosis,16-N-0055,National Institute of Neurological Disorders and Stroke (NINDS),United States
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,United States
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Belgium
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Bulgaria
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Canada
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Germany
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Poland
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Russian Federation
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Serbia
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Spain
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,2015-005160-41,Biogen,Ukraine
597,598,NCT02511028,"In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",15-N-0156,National Institute of Neurological Disorders and Stroke (NINDS),United States
605,606,NCT02486640,Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon,BF1502,Bayer,Germany
620,621,NCT02428231,Tecfidera Slow-Titration Study,2014-004562-22,Biogen,United States
620,621,NCT02428231,Tecfidera Slow-Titration Study,2014-004562-22,Biogen,Belgium
620,621,NCT02428231,Tecfidera Slow-Titration Study,2014-004562-22,Biogen,Czech Republic
620,621,NCT02428231,Tecfidera Slow-Titration Study,2014-004562-22,Biogen,Italy
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,United States
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Bulgaria
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Czech Republic
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Finland
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Italy
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Lithuania
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Netherlands
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Poland
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Russian Federation
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,Serbia
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,2013-003600-40,Biogen,United Kingdom
706,707,NCT02121444,"BAY86-5046 (Betaseron), Non Interventional Studies",BF1414DE,Bayer,Germany
722,723,NCT02046629,A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers,U1111-1152-4217,Sanofi,China
741,742,NCT01973491,ATX-MS-1467 in Multiple Sclerosis,2013-002916-28,"Merck KGaA, Darmstadt, Germany",Germany
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,United States
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Austria
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Belgium
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Canada
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Chile
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Finland
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,France
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Germany
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Greece
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Italy
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Norway
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Spain
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,Sweden
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,U1111-1139-8730,Sanofi,United Kingdom
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,United States
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Australia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Austria
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Belarus
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Brazil
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Bulgaria
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Canada
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Croatia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Estonia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,France
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Germany
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Italy
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Latvia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Lithuania
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Mexico
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Netherlands
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Poland
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Puerto Rico
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Romania
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Russian Federation
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Serbia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Slovakia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Spain
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Sweden
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Turkey
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,Ukraine
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,2011-005677-23,Novartis Pharmaceuticals,United Kingdom
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Belgium
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Czech Republic
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,France
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Italy
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Japan
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Poland
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Russian Federation
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Spain
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Sweden
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,2012-004019-29,Novartis Pharmaceuticals,Turkey
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,United States
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Canada
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Czech Republic
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,France
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Hungary
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Italy
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Netherlands
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Poland
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Russian Federation
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Serbia
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,Spain
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",2011-006262-40,Biogen,United Kingdom
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,U1111-1139-8802,Sanofi,Belgium
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,U1111-1139-8802,Sanofi,Germany
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,U1111-1139-8802,Sanofi,Netherlands
767,768,NCT01851434,Natural History of Optic Neuritis,13-N-0104,National Institute of Neurological Disorders and Stroke (NINDS),United States
767,768,NCT01851434,Natural History of Optic Neuritis,13-N-0104,National Institute of Neurological Disorders and Stroke (NINDS),Israel
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Austria
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Belgium
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Canada
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Czech Republic
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Denmark
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Finland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,France
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Germany
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Hungary
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Israel
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Italy
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Netherlands
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Norway
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Poland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Portugal
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Slovenia
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Spain
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Sweden
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,Switzerland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,2012-005262-35,Bayer,United Kingdom
790,791,NCT01766063,"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon",BF1212DE,Bayer,Germany
805,806,NCT01706055,Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE),BF1213PL,Bayer,Poland
821,822,NCT01617395,Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility,12-N-0122,National Institute of Neurological Disorders and Stroke (NINDS),United States
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,Belgium
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,Canada
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,Italy
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,Netherlands
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,Sweden
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,2012-000368-90,Biogen,United Kingdom
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Albania
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Algeria
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Argentina
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Belgium
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Czechia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Egypt
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,France
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Germany
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Greece
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Hungary
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Israel
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Kazakhstan
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Netherlands
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Portugal
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Saudi Arabia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Tunisia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,BF1101,Bayer,Turkey
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",2011-001629-25,Novartis Pharmaceuticals,Czech Republic
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",2011-001629-25,Novartis Pharmaceuticals,Russian Federation
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",2011-001629-25,Novartis Pharmaceuticals,Ukraine
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,2011-001160-21|U1111-1115-2742,Sanofi,Austria
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,2011-001160-21|U1111-1115-2742,Sanofi,Canada
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,2011-001160-21|U1111-1115-2742,Sanofi,Germany
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,2011-001160-21|U1111-1115-2742,Sanofi,Russian Federation
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,2011-001160-21|U1111-1115-2742,Sanofi,Ukraine
890,891,NCT01354665,Depression and Fatigue in MS Patients Treated With Betaferon.,BF1012PL,Bayer,Poland
895,896,NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,2010-023023-19,Novartis Pharmaceuticals,Germany
895,896,NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,2010-023023-19,Novartis Pharmaceuticals,Italy
899,900,NCT01326715,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,11-N-0116,National Institute of Neurological Disorders and Stroke (NINDS),United States
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,United States
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Belgium
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Canada
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Czech Republic
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Germany
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Greece
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Japan
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Poland
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Russian Federation
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Spain
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),2010-018705-11,EMD Serono,Ukraine
915,916,NCT01226654,Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis,2R01NS029029-16A1,NYU Langone Health,United States
919,920,NCT01212094,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),10-N-0212,National Institute of Neurological Disorders and Stroke (NINDS),United States
925,926,NCT01198132,A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 g 3 Times Weekly,2009-013695-46,"Merck KGaA, Darmstadt, Germany",France
929,930,NCT01184833,Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis,BF0813PL,Bayer,Poland
954,955,NCT01076595,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period",BF0910FR,Bayer,France
967,968,NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,20Y-LTF,Bayer,United States
967,968,NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,20Y-LTF,Bayer,Canada
972,973,NCT01013350,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials,2009-017978-21,EMD Serono,United States
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,Austria
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,Belgium
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,Finland
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,Germany
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,Israel
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,BF0802,Bayer,United Kingdom
991,992,NCT00928967,"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",Daily Life Study|BF0610FR,Bayer,France
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Belgium
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Canada
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Czech Republic
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,France
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Germany
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Greece
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Hungary
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Italy
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Poland
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Spain
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Switzerland
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,Tunisia
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,2008-006226-34,Sanofi,United Kingdom
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Australia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Austria
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Bahrain
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Belgium
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Canada
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Colombia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Czech Republic
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Denmark
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Egypt
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,France
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Germany
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Greece
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Indonesia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Israel
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Italy
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Jordan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Kazakhstan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,"Korea, Republic of"
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Kuwait
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Lebanon
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Mexico
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Netherlands
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Norway
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Oman
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Portugal
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Slovenia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Spain
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Sweden
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Switzerland
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Taiwan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,Thailand
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,United Arab Emirates
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),BF0601|310721,Bayer,United Kingdom
2,1003,NCT00873340,Physical Disability in Patients Treated With Betaferon,BF0712CO|2007- 001 Col,Bayer,Colombia
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,United States
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,Canada
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,Finland
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,France
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,Germany
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,Norway
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",2008-001999-67,Sanofi,Spain
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,United States
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,Austria
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,Canada
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,Germany
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,Italy
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,Spain
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,HMR1726D/2005|2007-003997-24,Sanofi,United Kingdom
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,United States
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Austria
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Canada
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Chile
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Czech Republic
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Denmark
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Estonia
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Finland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,France
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Germany
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Italy
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Netherlands
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Norway
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Poland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Portugal
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Russian Federation
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Sweden
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Switzerland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Turkey
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,Ukraine
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,2006-003361-14,Sanofi,United Kingdom
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,United States
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Australia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Austria
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Belarus
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Belgium
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Canada
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Chile
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,China
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Czech Republic
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Estonia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,France
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Germany
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Greece
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Mexico
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Netherlands
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Philippines
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Poland
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Romania
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Slovakia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Spain
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Sweden
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Thailand
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Tunisia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Turkey
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,Ukraine
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,2007-004452-36,Sanofi,United Kingdom
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,United States
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Australia
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Austria
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Bulgaria
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Canada
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Chile
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Czech Republic
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Denmark
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Estonia
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Finland
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,France
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Germany
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Hungary
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Lithuania
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Mexico
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Poland
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Romania
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Russian Federation
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Turkey
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,Ukraine
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,HMR1726D-3005|2006-001152-12,Sanofi,United Kingdom
51,1052,NCT00618267,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow"" Assay.",Biogen Idec 014-07-NAT,Biogen,United States
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Austria
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Belgium
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Canada
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Czech Republic
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Denmark
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Finland
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,France
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Germany
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Hungary
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Israel
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Italy
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Netherlands
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Norway
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Poland
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Slovenia
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Spain
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Sweden
58,1059,NCT00544037,BENEFIT Extension Study,311129,Bayer,Switzerland
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,2006-003134-14|HMR1726D-2003,Sanofi,United States
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,2006-003134-14|HMR1726D-2003,Sanofi,Canada
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,2006-003134-14|HMR1726D-2003,Sanofi,Germany
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,2006-003134-14|HMR1726D-2003,Sanofi,Italy
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,2006-003134-14|HMR1726D-2003,Sanofi,Spain
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,United States
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,Austria
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,Canada
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,Germany
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,Italy
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,2006-004893-29|HMR1726D-2004,Sanofi,United Kingdom
87,1088,NCT00432900,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,07-N-0092,National Institute of Neurological Disorders and Stroke (NINDS),United States
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Argentina
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Australia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Austria
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Belgium
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Bulgaria
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Canada
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Croatia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Czech Republic
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Estonia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Finland
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",France
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Germany
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Greece
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Israel
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Italy
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Latvia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Lebanon
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Morocco
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Poland
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Portugal
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Romania
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Russian Federation
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Saudi Arabia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Serbia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Slovakia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Spain
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),2006-002982-38,"Merck KGaA, Darmstadt, Germany",Turkey
97,1098,NCT00393588,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,07-N-0014,National Institute of Neurological Disorders and Stroke (NINDS),United States
101,1102,NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250g in Patients of Chinese Origin With Multiple Sclerosis",MP-00102|308720|2014-004613-93,Bayer,China
105,1106,NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,02-N-N196,National Institute of Neurological Disorders and Stroke (NINDS),United States
112,1113,NCT00325988,Biomarkers in Multiple Sclerosis,05-N-0063,National Institute of Neurological Disorders and Stroke (NINDS),United States
115,1116,NCT00321568,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,06-N-0154,National Institute of Neurological Disorders and Stroke (NINDS),United States
116,1117,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",EudraCT: 2005-001540-23|309560,Bayer,Denmark
116,1117,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",EudraCT: 2005-001540-23|309560,Bayer,Sweden
126,1127,NCT00262314,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",19-297,EMD Serono,United States
137,1138,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,HMR1726D/2002,Sanofi,Canada
137,1138,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,HMR1726D/2002,Sanofi,France
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Austria
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Belgium
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Canada
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Czech Republic
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Denmark
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Finland
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,France
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Germany
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Hungary
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Israel
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Italy
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Netherlands
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Norway
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Poland
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Portugal
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Slovenia
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Spain
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Sweden
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,Switzerland
150,1151,NCT00185211,BENEFIT Study (Betaferon / Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,305207,Bayer,United Kingdom
153,1154,NCT00166283,Improving New Learning and Memory in Multiple Sclerosis,R01HD045798,Kessler Foundation,United States
158,1159,NCT00142402,Modafinil in Multiple Sclerosis,PP0911,Kessler Foundation,United States
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,United States
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Austria
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Canada
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Chile
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Czech Republic
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Denmark
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Estonia
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Finland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,France
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Germany
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Italy
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Netherlands
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Norway
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Poland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Portugal
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Russian Federation
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Sweden
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Switzerland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Turkey
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,Ukraine
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,2004-000555-42|HMR1726D/3001,Sanofi,United Kingdom
170,1171,NCT00099307,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,05-N-0039,National Institute of Neurological Disorders and Stroke (NINDS),United States
188,1189,NCT00011375,Rolipram to Treat Multiple Sclerosis,01-N-0089,National Institute of Neurological Disorders and Stroke (NINDS),United States
195,1196,NCT00001934,Zenapax to Treat Multiple Sclerosis,99-N-0169,National Institute of Neurological Disorders and Stroke (NINDS),United States
196,1197,NCT00001781,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",98-N-0069,National Institute of Neurological Disorders and Stroke (NINDS),United States
197,1198,NCT00001669,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,97-N-0148,National Institute of Neurological Disorders and Stroke (NINDS),United States
198,1199,NCT00001248,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),89-N-0045,National Institute of Neurological Disorders and Stroke (NINDS),United States
211,1212,NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),10-N-0125,National Institute of Neurological Disorders and Stroke (NINDS),United States
212,1213,NCT00461396,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",311501|BF0713US,Bayer,United States
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,United States
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Belgium
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Bulgaria
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Kuwait
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Lithuania
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Poland
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,2015-001973-42,Biogen,Turkey
221,1222,NCT02423083,Oral Guanabenz for Multiple Sclerosis,15-N-0117,National Institute of Neurological Disorders and Stroke (NINDS),United States
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Austria
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Belgium
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Canada
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Czechia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,France
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Hungary
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Italy
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Portugal
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Slovakia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Slovenia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,2013-001656-35,Biogen,Spain
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2013-004533-32,Biogen,Czechia
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2013-004533-32,Biogen,Japan
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2013-004533-32,Biogen,"Korea, Republic of"
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2013-004533-32,Biogen,Poland
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2013-004533-32,Biogen,Taiwan
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,United States
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Argentina
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Australia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Brazil
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Canada
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Czechia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Denmark
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,France
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Georgia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Germany
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Greece
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Hungary
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,India
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Ireland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Israel
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Italy
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Mexico
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,"Moldova, Republic of"
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Poland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Romania
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Russian Federation
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Serbia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Spain
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Sweden
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Switzerland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,Ukraine
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,2012-003176-39,Biogen,United Kingdom
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,United States
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Argentina
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Australia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Austria
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Belgium
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Brazil
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Canada
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Chile
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Colombia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Denmark
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Estonia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Finland
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,France
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Germany
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Greece
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Hungary
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Italy
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,"Korea, Republic of"
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Lithuania
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Netherlands
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Norway
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Portugal
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Russian Federation
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Slovakia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Spain
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Sweden
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,Tunisia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,2010-023172-12|U1111-1115-2414,Sanofi,United Kingdom
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,United States
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Austria
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Brazil
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Bulgaria
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Canada
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Denmark
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,France
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Greece
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Italy
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,"Korea, Republic of"
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Mexico
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Poland
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Russian Federation
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2020-001168-28,Hoffmann-La Roche,Turkey
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,United States
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Argentina
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Finland
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Germany
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Hong Kong
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Italy
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Peru
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Portugal
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Russian Federation
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Spain
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Taiwan
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),2019-004857-10,Hoffmann-La Roche,Ukraine
249,1250,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","111,116",Novartis Pharmaceuticals,United States
249,1250,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","111,116",Novartis Pharmaceuticals,Puerto Rico
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,United States
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Argentina
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Belgium
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Brazil
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Canada
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Chile
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Croatia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Czechia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,France
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Germany
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Greece
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Hungary
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,India
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Israel
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,"Korea, Republic of"
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Latvia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Netherlands
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Norway
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Portugal
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Puerto Rico
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Russian Federation
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Serbia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Slovakia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Spain
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Turkey
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,Ukraine
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1373,Sanofi,United Kingdom
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,United States
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Belarus
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Bulgaria
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Canada
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,China
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Czechia
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Denmark
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Estonia
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Finland
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Germany
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Italy
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Japan
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Lithuania
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Poland
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Romania
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Russian Federation
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Spain
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Sweden
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Taiwan
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Turkey
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1418,Sanofi,Ukraine
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,United States
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Australia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Austria
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Belgium
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Bulgaria
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Canada
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Czechia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Germany
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Greece
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Hungary
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Italy
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Lebanon
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Mexico
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Norway
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Poland
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Portugal
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Russian Federation
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Saudi Arabia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Slovakia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Spain
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Switzerland
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,2019-001341-40,Novartis Pharmaceuticals,Turkey
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,United States
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Canada
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Czechia
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Estonia
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,France
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Netherlands
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Russian Federation
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Spain
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,2018-004731-76|U1111-1223-4256,Sanofi,Ukraine
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,United States
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Canada
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Czechia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Estonia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,France
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Netherlands
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Russian Federation
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Slovakia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Spain
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,2018-003927-12|U1111-1220-0572,Sanofi,Ukraine
261,1262,NCT03856619,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,U1111-1205-3009,Sanofi,India
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,United States
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Argentina
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Australia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Belgium
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Bulgaria
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Canada
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Croatia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Czechia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Denmark
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Estonia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,France
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Germany
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Greece
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Hungary
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,India
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Israel
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Italy
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Mexico
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Netherlands
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Poland
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Puerto Rico
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Russian Federation
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Slovakia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Spain
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Sweden
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Switzerland
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Thailand
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,Turkey
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2015-005418-31,Novartis Pharmaceuticals,United Kingdom
269,1270,NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,2013-005586-39,Biogen,United States
271,1272,NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,2014-000917-30,Biogen,Belgium
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,United States
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Argentina
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Belarus
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Belgium
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Bosnia and Herzegovina
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Brazil
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Bulgaria
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Canada
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Croatia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Czechia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,France
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Germany
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Ireland
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Italy
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Mexico
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Norway
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Poland
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Russian Federation
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Slovakia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Spain
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Sweden
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Turkey
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,Ukraine
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020315-36,Hoffmann-La Roche,United Kingdom
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,United States
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Belgium
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Bulgaria
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Canada
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Chile
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Colombia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Croatia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Czech Republic
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Estonia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,France
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Georgia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Germany
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Greece
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,India
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Latvia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Mexico
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Netherlands
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,New Zealand
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Peru
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Poland
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Romania
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Russian Federation
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Serbia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Spain
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,Ukraine
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,2010-024477-39,Biogen,United Kingdom
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,United States
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Argentina
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Australia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Austria
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Belgium
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Brazil
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Bulgaria
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Chile
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Czechia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Estonia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Finland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,France
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Germany
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Hungary
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Israel
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Italy
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Latvia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Lithuania
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Mexico
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Netherlands
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Peru
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Poland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Portugal
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Russian Federation
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Serbia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Slovakia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,South Africa
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Spain
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Switzerland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Tunisia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,Ukraine
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2010-020337-99,Hoffmann-La Roche,United Kingdom
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,United States
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Belgium
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Bulgaria
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Canada
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Chile
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Colombia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Croatia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Czech Republic
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Estonia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,France
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Georgia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Germany
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Greece
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,India
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Latvia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Mexico
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Netherlands
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,New Zealand
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Peru
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Poland
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Romania
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Russian Federation
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Serbia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Spain
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,Ukraine
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,2008-006333-27,Biogen,United Kingdom
302,1303,NCT02977533,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,2016-002415-18|U1111-1184-8607,Sanofi,Germany
337,1338,NCT04982991,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,2021-001076-42|U1111-1264-3008,Sanofi,United Kingdom
349,1350,NCT02323269,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),CAN-BGT-14-10614,Biogen,Canada
365,1366,NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,2011-002969-38,Novartis Pharmaceuticals,Germany
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,United States
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Argentina
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Australia
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Austria
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Brazil
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Canada
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Denmark
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,France
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Greece
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Hungary
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Israel
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Mexico
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Peru
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Poland
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Portugal
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Puerto Rico
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Russian Federation
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Spain
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Turkey
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,Ukraine
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,2019-003919-53,Hoffmann-La Roche,United Kingdom
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,United States
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Argentina
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Australia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Belgium
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Bulgaria
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Croatia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Czechia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,France
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Germany
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Greece
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Hungary
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Israel
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Italy
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Kuwait
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Portugal
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Russian Federation
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Saudi Arabia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Serbia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Slovakia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Spain
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Tunisia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",2018-003008-38,Biogen,Turkey
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,United States
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Colombia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Estonia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Hungary
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Jordan
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,"Korea, Republic of"
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Malaysia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Mexico
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Saudi Arabia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Taiwan
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Thailand
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Tunisia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,2018-000516-22,Biogen,Turkey
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,United States
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Australia
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Belgium
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Canada
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,France
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Germany
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Israel
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Italy
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Netherlands
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,Spain
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-002145-11,Biogen,United Kingdom
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,United States
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Argentina
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Australia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Austria
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Belgium
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Brazil
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Bulgaria
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Canada
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Croatia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Denmark
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,France
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Germany
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Hungary
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Italy
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Kuwait
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Lebanon
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Mexico
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Netherlands
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Norway
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Poland
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Portugal
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Romania
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Slovakia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Slovenia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Spain
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Sweden
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Switzerland
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,Turkey
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2016-002937-31,Hoffmann-La Roche,United Kingdom
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Australia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Belgium
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Czechia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Denmark
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Estonia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Finland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,France
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Germany
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Ireland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Italy
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Netherlands
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Norway
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Spain
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Sweden
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Switzerland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,Turkey
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),2015-005597-38,Hoffmann-La Roche,United Kingdom
432,1433,NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,2013-001422-25|109MS410,Biogen,Italy
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,United States
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Belgium
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Bulgaria
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Czechia
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Germany
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Kuwait
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Latvia
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Lebanon
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Poland
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),2015-003282-29,Biogen,Turkey
434,1435,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,2015-001357-32,Hoffmann-La Roche,United States
434,1435,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,2015-001357-32,Hoffmann-La Roche,Canada
438,1439,NCT02471560,Tecfidera and the Gut Microbiota,2015-001197-18,Biogen,Norway
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,United States
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Belgium
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Bulgaria
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Czechia
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Germany
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Kuwait
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Latvia
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Lebanon
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Poland
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,2014-005003-24,Biogen,Turkey
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Austria
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Belgium
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Bosnia and Herzegovina
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Croatia
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Czechia
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,France
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Greece
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Hungary
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Italy
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Spain
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BF1401,Bayer,Switzerland
450,1451,NCT02064816,A Study of Rebif in Subjects With Relapsing Multiple Sclerosis,2013-004450-21,"Merck KGaA, Darmstadt, Germany",Germany
456,1457,NCT01667796,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,FG-1507-05231,Johns Hopkins University,United States
462,1463,NCT01436838,"China Betaferon Adherence, Coping and Nurse Support Study",BF1110CN,Bayer,China
466,1467,NCT01420055,Fingolimod -Response According to Coping - Evaluation,2011-001280-49,Novartis Pharmaceuticals,France
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,United States
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Australia
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Austria
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Belgium
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Brazil
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Bulgaria
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Canada
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Czechia
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Finland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,France
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Germany
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Greece
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Hungary
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Israel
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Italy
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Lithuania
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Mexico
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Netherlands
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,New Zealand
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Norway
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Peru
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Poland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Portugal
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Romania
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Russian Federation
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Spain
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Switzerland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Ukraine
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,United Kingdom
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2010-020338-25,Hoffmann-La Roche,Uruguay
474,1475,NCT01158183,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,BF0714US|311644,Bayer,United States
478,1479,NCT01134627,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif) in Relapsing-Remitting Multiple Sclerosis [RRMS],2005-004289-18,"Merck KGaA, Darmstadt, Germany",Denmark
488,1489,NCT01071694,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon in Korea,Qolbet|BF1010KR,Bayer,"Korea, Republic of"
492,1493,NCT00780455,Rehabilitation Study in MS Patients,2006-006673-24|308083,Bayer,France
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,United States
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Argentina
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Australia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Austria
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Belgium
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Brazil
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Canada
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Denmark
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Finland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,France
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Germany
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Greece
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Hungary
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Ireland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Israel
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Italy
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Latvia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Netherlands
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Norway
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Poland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Russian Federation
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Slovenia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Spain
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Sweden
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Switzerland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose,2006-005270-47|309363,Bayer,Ukraine
505,1506,NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron to Treat Relapsing-remitting Multiple Sclerosis,307320|Beyond,Bayer,United States
509,1510,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,307245,Bayer,United States
509,1510,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,307245,Bayer,Canada
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,United States
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Argentina
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Australia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Austria
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Belgium
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Brazil
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Canada
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Denmark
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Finland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,France
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Germany
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Greece
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Hungary
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Ireland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Israel
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Italy
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Latvia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Netherlands
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Norway
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Poland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Russian Federation
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Slovenia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Spain
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Sweden
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Switzerland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,EudraCT: 2005-002235-27|306440|Beyond,Bayer,Ukraine
514,1515,NCT00071838,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,04-N-0019,National Institute of Neurological Disorders and Stroke (NINDS),United States
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,United States
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,Belgium
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,Czech Republic
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,Netherlands
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,Poland
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,2014-003021-18,Biogen,Slovakia
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,2013-002324-16,Novartis Pharmaceuticals,United States
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,2013-002324-16,Novartis Pharmaceuticals,Czechia
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,2013-002324-16,Novartis Pharmaceuticals,Ukraine
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,United States
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Argentina
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Australia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Austria
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Belarus
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Belgium
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Bulgaria
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Canada
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Chile
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,China
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Colombia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Croatia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Czechia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Denmark
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Estonia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,France
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Germany
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Greece
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Hungary
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,India
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Israel
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Italy
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Japan
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Latvia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Netherlands
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Norway
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Poland
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Portugal
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Romania
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Russian Federation
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Serbia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Spain
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Sweden
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Switzerland
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Turkey
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,Ukraine
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1238-1318,Sanofi,United Kingdom
562,1563,NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,2016-000434-21,Biogen,Portugal
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,2017-001294-16,Biogen,United States
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,2017-001294-16,Biogen,Germany
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,2017-001294-16,Biogen,Poland
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,United States
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Australia
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Czechia
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,France
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Germany
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Italy
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Spain
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,Sweden
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,2013-004622-29,Biogen,United Kingdom
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,United States
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Belgium
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Bulgaria
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Canada
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Czechia
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Denmark
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,France
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Germany
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Hungary
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Israel
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Italy
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Kuwait
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Poland
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Serbia
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Spain
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Sweden
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,Turkey
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),2013-002318-11,Biogen,United Kingdom
596,1597,NCT02159573,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",US-BGT-13-10564,Biogen,United States
598,1599,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,2013-001486-17,Biogen,Germany
600,1601,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,2013-001895-40,Biogen,Ireland
600,1601,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,2013-001895-40,Biogen,United Kingdom
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,United States
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Bulgaria
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Croatia
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Czech Republic
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Finland
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Greece
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Hungary
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Italy
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Mexico
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Poland
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Russian Federation
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Serbia
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,South Africa
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Spain
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Turkey
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,Ukraine
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",2013-002283-25,EMD Serono,United Kingdom
609,1610,NCT01884935,PK and PD Study of Natalizumab in Pediatric Subjects With RRMS,2012-005082-13,Biogen,Italy
611,1612,NCT01808885,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,2012-005186-12|TRO19622CLEQ1585-1,Hoffmann-La Roche,France
630,1631,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,2011-003484-30,Novartis Pharmaceuticals,Australia
630,1631,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,2011-003484-30,Novartis Pharmaceuticals,Spain
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,2010-023856-97,Biogen,United States
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,2010-023856-97,Biogen,Czech Republic
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,2010-023856-97,Biogen,Hungary
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,2010-023856-97,Biogen,Poland
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",2010-024000-10,Biogen,Belgium
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",2010-024000-10,Biogen,France
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",2010-024000-10,Biogen,Germany
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",2010-024000-10,Biogen,Italy
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",2010-024000-10,Biogen,Spain
642,1643,NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,2010-024017-31,Novartis Pharmaceuticals,Italy
643,1644,NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,2010-022066-28,Novartis Pharmaceuticals,Germany
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Austria
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Denmark
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Estonia
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Finland
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Germany
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Italy
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Latvia
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Lithuania
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Netherlands
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Norway
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Portugal
645,1646,NCT01285401,Supplementation of VigantOL Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif Treatment,2010-020328-23,"Merck KGaA, Darmstadt, Germany",Switzerland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,United States
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Canada
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Finland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Germany
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Hungary
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Italy
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Norway
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Poland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Russian Federation
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Spain
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Switzerland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",2009-014392-51,Novartis Pharmaceuticals,Turkey
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,United States
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Argentina
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Australia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Brazil
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Canada
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Czech Republic
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Denmark
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Finland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,France
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Georgia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Germany
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Greece
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Hungary
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,India
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Ireland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Israel
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Italy
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Mexico
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,"Moldova, Republic of"
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Poland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Romania
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Russian Federation
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Serbia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Spain
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Sweden
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Switzerland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,Ukraine
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis,2009-012500-11,Biogen,United Kingdom
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Czechia
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Germany
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Hungary
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,India
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Poland
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Russian Federation
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,Ukraine
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,2009-015318-23,Biogen,United Kingdom
668,1669,NCT00902135,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",BF0801DE,Bayer,Germany
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,United States
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Canada
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Finland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Germany
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Hungary
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Italy
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Norway
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Poland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Russian Federation
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Spain
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Switzerland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",2008-008719-25,Novartis Pharmaceuticals,Turkey
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Czech Republic
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Germany
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Hungary
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,India
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Poland
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Russian Federation
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,Ukraine
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,EUDRA CT No.: 2008-005559-46,Biogen,United Kingdom
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,United States
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Australia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Austria
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Belarus
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Belgium
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Bosnia and Herzegovina
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Bulgaria
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Canada
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Croatia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Czechia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Estonia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,France
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Germany
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Greece
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,India
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Ireland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Israel
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Italy
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Latvia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Mexico
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,"Moldova, Republic of"
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Netherlands
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,New Zealand
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,North Macedonia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Poland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Puerto Rico
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Romania
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Serbia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Slovakia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,South Africa
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Spain
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Switzerland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,Ukraine
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),2008-004753-14,Biogen,United Kingdom
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,United States
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Australia
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Belgium
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Canada
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Czechia
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Denmark
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Finland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,France
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Germany
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Hungary
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Italy
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Netherlands
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Poland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Spain
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Sweden
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Switzerland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,Turkey
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",2007-002627-32,Novartis Pharmaceuticals,United Kingdom
703,1704,NCT00317941,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,2005-005583-91|308084|Avantage,Bayer,France
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Belgium
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Denmark
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Finland
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Netherlands
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Norway
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Sweden
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,Switzerland
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,Mecombin,Biogen,United Kingdom
725,1726,NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),2020-005752-38,Novartis Pharmaceuticals,Germany
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,United States
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Argentina
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Australia
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Austria
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Belarus
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Belgium
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Bulgaria
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Canada
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,China
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Czechia
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Denmark
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Finland
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,France
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Germany
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Greece
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Hungary
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,India
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Israel
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Italy
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Japan
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Lithuania
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Netherlands
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Norway
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Poland
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Portugal
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Romania
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Russian Federation
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Spain
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Turkey
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,Ukraine
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),U1111-1246-7768,Sanofi,United Kingdom
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,United States
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Belgium
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Canada
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Czechia
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Denmark
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Finland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,France
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Germany
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Ireland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Israel
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Italy
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Netherlands
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Poland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Russian Federation
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Spain
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,Sweden
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,2010-021978-11,Biogen,United Kingdom
752,1753,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon,2018-001015-70,"Merck KGaA, Darmstadt, Germany",Germany
752,1753,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon,2018-001015-70,"Merck KGaA, Darmstadt, Germany",Poland
759,1760,NCT01235455,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",BF0710PT,Bayer,Portugal
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,United States
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Argentina
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Australia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Austria
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Belgium
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Brazil
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Canada
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Czechia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Denmark
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Egypt
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Estonia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Finland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,France
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Germany
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Greece
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Guatemala
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Hungary
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Ireland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Israel
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Italy
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Jordan
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,"Korea, Republic of"
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Malaysia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Netherlands
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Norway
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Panama
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Peru
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Poland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Portugal
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Romania
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Russian Federation
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Slovakia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,South Africa
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Spain
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Sweden
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Switzerland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,Turkey
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,2010-020515-37,Novartis Pharmaceuticals,United Kingdom
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,2016-002820-10,Biogen,United States
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,2016-002820-10,Biogen,Canada
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,2016-002820-10,Biogen,Germany
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,2016-002820-10,Biogen,Italy
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,2016-002820-10,Biogen,Puerto Rico
781,1782,NCT02587065,Plegridy Satisfaction Study in Participants,2015-002201-11,Biogen,Italy
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Australia
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Austria
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Czech Republic
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Finland
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Germany
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Greece
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Hungary
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Israel
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Italy
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Spain
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,2011-001442-15,Novartis Pharmaceuticals,Switzerland
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Argentina
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Bahrain
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Belgium
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Bosnia and Herzegovina
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Canada
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,China
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Colombia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Czech Republic
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Egypt
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Estonia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,France
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Germany
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,"Iran, Islamic Republic of"
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Israel
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Italy
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Jordan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,"Korea, Republic of"
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Kuwait
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Lebanon
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Libyan Arab Jamahiriya
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Mexico
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Netherlands
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,New Zealand
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Norway
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Pakistan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Portugal
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Saudi Arabia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Singapore
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Slovakia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Slovenia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Sweden
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Syrian Arab Republic
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Taiwan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,United Arab Emirates
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,United Kingdom
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,311941|BF0703,Bayer,Venezuela
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,United States
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,Canada
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,France
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,Germany
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,Italy
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,Spain
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,Switzerland
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,2021-000063-79,Hoffmann-La Roche,United Kingdom
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,United States
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,France
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,Germany
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,Italy
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,Spain
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,Switzerland
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,2021-000062-14,Hoffmann-La Roche,United Kingdom
882,1883,NCT03677440,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,1R01HD091155-01A1,Kessler Foundation,United States
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,United States
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Australia
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Canada
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Czechia
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Denmark
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Germany
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Italy
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Netherlands
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Poland
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Spain
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,Switzerland
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,2011-001437-16,Novartis Pharmaceuticals,United Kingdom
946,1947,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif With the RebiSmart Device,2012-004887-22,"Merck KGaA, Darmstadt, Germany",Germany
946,1947,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif With the RebiSmart Device,2012-004887-22,"Merck KGaA, Darmstadt, Germany",Sweden
958,1959,NCT01414816,Betaferon Regulatory Post-Marketing Surveillance,BF0814KR,Bayer,"Korea, Republic of"
976,1977,NCT00893217,BEYOND Pilot Study,BEYOND pilot|307000,Bayer,United States
978,1979,NCT00845338,Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity,2006-002361-39,Bayer,Germany
18,2019,NCT02641041,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",2015-004560-11,Biogen,United Kingdom
43,2044,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,2008-000981-22,Bayer,Australia
43,2044,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,2008-000981-22,Bayer,Sweden
75,2076,NCT02254304,Effectiveness of Rebif in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart,2014-001290-14,"Merck KGaA, Darmstadt, Germany",Germany
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,2009-011626-34,Novartis Pharmaceuticals,Czech Republic
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,2009-011626-34,Novartis Pharmaceuticals,Russian Federation
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,2009-011626-34,Novartis Pharmaceuticals,Ukraine
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,2008-008065-35,Biogen,Austria
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,2008-008065-35,Biogen,Denmark
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,2008-008065-35,Biogen,Norway
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,2008-008065-35,Biogen,Sweden
107,2108,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,2011-001692-39,Novartis Pharmaceuticals,Germany
179,2180,NCT00376506,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,06-N-0212,National Institute of Neurological Disorders and Stroke (NINDS),United States
191,2192,NCT02504840,Natural History of Multiple Sclerosis and Its Mimickers,15-N-0158,National Institute of Neurological Disorders and Stroke (NINDS),United States
